Alkermes’ Aristada Initio Approved By FDA For Schizophrenia

Alkermes plc. recently announced that the Food & Drug Administration (FDA) approved Aristada Initio (aripiprazole lauroxil) for schizophrenia in adults. The approval makes the drug the first and only long-acting atypical antipsychotic that can be initiated on day one for the treatment of schizophrenia.

Compared to Alkermes’ injectable atypical antipsychotic medication, Aristada, Aristada Initio utilizes a smaller particle size, provides faster dissolution, and allows clinical professionals and caregivers to fully dose individuals for up to two months. It is anticipated that the drug will become available this month.

Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative . . .